-
1
The gut microbiome plays a crucial role in regulating immunity, metabolism, and inflammation, impacting cancer progression and treatment responses.
-
2
Triple-negative breast cancer (TNBC) is aggressive, accounting for 10–15% of breast cancers, and is primarily treated with chemotherapy and immunotherapy.
-
3
Dysbiosis in the gut microbiome is linked to worse outcomes in TNBC, while higher microbial diversity correlates with improved treatment responses.
-
4
Obesity significantly influences TNBC risk by promoting chronic inflammation and altering gut microbiota, which can affect tumor growth and immune response.
-
5
Emerging strategies, including dietary modulation and microbiome-targeted interventions, may optimize TNBC management and improve patient outcomes.
